Resilience raises over $800 million to change pharmaceutical manufacturing in response to COVID-19
Durability, a brand-new biopharmaceutical business backed by $800 million in financing from investors including ARCH Endeavor Partners and 8VC, has emerged from stealth to change the way that treatments and drugs are manufactured in the U.S. Founded by ARCH Endeavor Partners investor Robert Nelsen, National Strength Inc., which does business as Durability, was born out […]…
Recent Comments